Progesterone regulates uterine function during the luteal phase and is essential for the acquisition of endometrial receptivity. The objective of the present study was to identify endometrial transcripts whose expression is altered during the window of implantation after the administration of 200 mg of the antiprogestin mifepristone, 48 h after the LH peak (LHC2, LHC0ZLH peak), and to determine the relationship of these transcripts with those regulated during the acquisition of receptivity. Endometrial samples were obtained in LHC7 from seven women of proven fertility, each one contributing with one cycle treated with placebo and another with mifepristone. Additionally, endometrial samples were obtained in LHC2 and LHC7 during a single untreated spontaneous cycle from seven normal fertile women as a reference. DNA microarrays were used to identify transcripts significantly regulated (defined as R2.0-fold change with false discovery rate below 1% using t-test) with the administration of mifepristone vs placebo, or during the transition from pre-receptive to receptive (LHC2 vs LHC7). Approximately 2000 transcripts were significantly regulated in both comparisons (mifepristone vs placebo and LHC2 vs LHC7), but only 777 of them were coincident and displayed opposite regulation except for 25. The mRNA level for eight selected genes regulated by mifepristone was confirmed by real-time RT-PCR. We conclude that not all changes in endometrial transcript levels occurring in the transition from LHC2 to LHC7 seem to be regulated by the progesterone receptor and w37% of the genes whose transcript levels changed by effect of mifepristone could be associated with the acquisition of receptivity.
Introduction
Human endometrium displays characteristic morphological and molecular changes during each stage of development during menstrual cycle under the control of the ovarian hormones estradiol and progesterone (P 4 ). Both epithelial and stromal cells undergo mitosis in response to rising estradiol serum levels during the proliferative phase of the endometrial cycle whereas the secretory phase is driven by P 4 (Bagchi et al. 2003) , which triggers a highly coordinated and sequential responses beginning with the suppression of the estrogen-dependent epithelial cell proliferation and inducing endometrial differentiation and maturation characterized by the secretory transformation of the glands, infiltration of immune cells and stromal edema (Strowitzki et al. 2006 , Gellersen et al. 2007 . At functional level, P 4 renders the uterus in an adequate morphological and functional state for embryo implantation during a self-limited time (Paria et al. 2002) . This period, so-called window of implantation, lasts for 5 days starting on day 20 (day LH C7-11) of a 28-days menstrual cycle (Navot et al. 1991 , Wilcox et al. 1999 . On target cells, P 4 exerts its effects primarily through the nuclear P 4 receptor (PGR) (Tsai & O'Malley 1994) , a member of the superfamily of ligand-activated transcription factors (Misrahi et al. 1987) . PGR is a ligand activated transcription factor (Chabbert-Buffet et al. 2005) which upon P 4 binding activates its gene regulatory functions (Graham & Clarke 1997) . The hormone-receptor complex interacts with specific target genes, modulating their expression. Two PGR isoforms have been described, PGR-A and PGR-B, which are transcribed from a single gene with two distinct promoters (O'Malley & Tsai 1992 ). In addition, P 4 may elicit several rapid signaling events, independent of transcriptional regulation or even in the absence of its nuclear receptors (Gellersen et al. 2009 ). It is accepted that these rapid non-genomic signaling events along with the relatively slower genomic actions, determine the functional response to P 4 in cell type-and milieuspecific manner. While the genomic responses are better understood, the mechanisms underlying non-genomic P 4 actions are mostly yet to be determined (Gellersen et al. 2009 ).
In the endometrium, P 4 regulates the expression and repression of genes during the period of receptivity that eventually induce a physiological state required to initiate and support pregnancy (Tabibzadeh 1998 , Wang & Dey 2006 . In women, most of P 4 -regulated genes in the endometrium that might be relevant in embryo implantation have been identified using DNA microarrays by comparing the endometrial gene expression profile of women during mid-secretory phase (peak circulating P 4 ) with proliferative or early secretory phase (low circulating P 4 ) in spontaneous cycles. Unfortunately, few genes that were significantly and similarly regulated during the window of implantation have been reported considering the total number of regulated transcripts comprising each list of six different reports (Tapia et al. 2011) . Since P 4 drives endometrial receptivity, chemical compounds that block P 4 action interfere with its transition to the secretory phenotype and avoid or interrupt pregnancy. One of this compounds is mifepristone (RU486), a synthetic 19 nor-steroid antagonist of the PGR ) that inhibits P 4 -mediated gene transcription and, if administered post-implantation, ultimately leads to conceptus abortion (Baulieu 1989) . The molecular mechanism of mifepristone action is not completely understood although it has been described that receptor activation, heat shock proteins dissociation, dimerization and binding to P 4 response elements in the DNA do not appear to be affected upon mifepristone binding to PGR. This suggests that the interaction and recruitment of corregulators (Liu et al. 2002) are the main factors driving its antiprogestin activity (Chauchereau et al. 2003 , Dasgupta & O'Malley 2014 , Szwarc et al. 2015 . In addition, mifepristone may act as P 4 antagonist for some non-genomic responses elicited by P 4 (Chien et al. 2009 ).
The effects of mifepristone in the endometrium depend on the dose and day of the menstrual cycle it is administered (Gemzell- . Its administration during the proliferative phase inhibits follicular development and delays the LH peak retarding ovulation. Consequently, the menstrual cycle length is extended without effects on endometrial morphology (Liu et al. 1987 , Swahn et al. 1988 . When mifepristone is administered during the mid or late luteal phase induces endometrial bleeding a few days after its administration (Schaison et al. 1985 , Shoupe et al. 1987 , Swahn et al. 1988 . When a single dose of mifepristone (200 mg) is administered 2 days after ovulation (i.e. 2 days after the LH surge, LHC2) affects neither the menstrual cycle length nor serum estrogen and P 4 levels, however it profoundly affects endometrial morphology, retarding endometrial development and inhibiting the glandular secretory activity (Swahn et al. 1990 ) which ultimately prevents pregnancy (GemzellDanielsson et al. 1993 , Hapangama et al. 2001 . Gemzell- reported the contraceptive effects of a single dose of mifepristone 200 mg in LHC2 to a group of women as their only contraceptive method. In 124 out of 157 cycles, sexual intercourse occurred during the fertile period and only one pregnancy was documented. Similar results were obtained in other study (Hapangama et al. 2001 ) using the same administration protocol and dose in which 136 out of 178 studied cycles were ovulatory and exposed, reporting only one pregnancy. Although these studies do not allow a pregnancy rate calculation (Croxatto 2003) , they reveal a clear contraceptive effect upon the administration of a single mifepristone dose during the early luteal phase (day LHC2). The evidence from the clinical studies and the reported effects on the endometrial morphology provide robust evidence that the changes produced in the endometrium during the receptive phase are enough for preventing embryo implantation. In addition, studies using co-culture of human embryos with in vitro endometrial constructions showed that mifepristone inhibits embryo adhesion to the endometrial layer (Lalitkumar et al. 2007 ). Mifepristone has been used previously to evaluate endometrial gene expression in vitro using tissue explants obtained during the mid-secretory phase (Catalano et al. 2003) . However, this model does not reflex the steroids dynamics occurring in vivo. Tissue explants are appropriate for evaluating immediate responses in human endometrium to ovarian steroids ex vivo but do not fully address the entire set of genes associated to embryo implantation (Catalano et al. 2007 , Dassen et al. 2007a . The endometrial response to 200 mg of mifepristone in day LHC8 was evaluated in women after 6 or 24 h of treatment (Catalano et al. 2007 ). Although this model was designed to identify P 4 -regulated genes involved in the endometrial receptivity, also pinpoints transcripts related to the induction of menstruation, introducing a confounding factor in the determination of uterine receptivity genes. The effect of mifepristone administration during the early luteal phase on human endometrial gene expression during the receptive period in vivo has not yet been studied. We hypothesize that the administration of mifepristone on LHC2 will inhibit P 4 -induced gene expression changes required for endometrial receptivity. Such design does not induces menses prematurely nor alters circulating estrogen and P 4 levels, allowing the evaluation of gene expression changes induced by mifepristone in receptive endometrium, under conditions that inhibit implantation without inducing menses. The objective of the present study is to identify endometrial genes whose transcript levels on LHC7 is altered upon administration of mifepristone on LHC2 and to determine their relation with the gene expression profile of the endometrium during the transition from pre-receptive (LHC2) to receptive (LHC7).
Materials and methods

Participants
The present study was conducted using a protocol in accordance with the guidelines in the Declaration of Helsinki and approved by the Ethical and Scientific Review Committee from Instituto Chileno de Medicina Reproductiva (ICMER). Each volunteer signed an informed consent form before participating. Two groups of seven women were recruited for the study, all of them having good health as determined by medical history, physical and gynecological examination. All volunteers were of Hispanic ethnicity, surgically sterilized at least 1 year before participating in the study for reasons unrelated to this study, regular menstrual cycles within the range of 26-35 days. Age, BMI and hemoglobin levels of all participating women are presented in Table 1 . No one was under chronic medication or taking hormones or drugs able to modify the metabolism of steroid hormones in the 3 preceding months. Functional and anthropometric and parameters of participating women are presented in Table 1 .
Study design
This study was comprised of two parts. The first one was a placebo controlled, cross-over, double-blinded and randomized trial that included seven volunteers. Each subject contributed with one placebo-treated cycle (control) and one mifepristone-treated cycle (experimental) in a randomized order and one endometrial biopsy was taken on day LHC7 (LHC0Zday of LH peak) of each cycle. Three women started with the control cycle and the other four with the experimental cycle. The following two cycles, no treatment was given (resting cycles) and no biopsy was taken. At the fourth consecutive cycle, a corresponding swap with experimental and control cycles was done.
In order to control the timing of the interventions and assure normality of the cycle under study, serum LH was measured daily starting from the mid follicular phase (days 7-10) and follicular growth was monitored by transvaginal ultrasound (TVU). Blood sampling and TVU were discontinued the following day after ovulation was detected. When the echo-image of the leading follicle was found to have disappeared or reduced at least 50%, was taken as evidence that ovulation had occurred. A single pill containing mifepristone 200 mg (HRA Pharma, Paris, France) or placebo was administered 48 h after the LH peak (LHC2) during the experimental and control cycles respectively and both types of pills were identical in appearance. Treatment was given at the clinic under supervision of a nurse in all cases. Endometrial samples were collected on LHC7 under sterile conditions from the uterine fundus, using pipelle catheters (Laboratoire C.C.D., Paris, France). An additional blood sample was taken on the biopsy day to determine P 4 serum level. The second part of the study involved another group of seven volunteers that met the same inclusion criteria as the group from the first part of our protocol. A straightforward follow up for a single menstrual cycle was done for these women that included daily serum LH measurements and TVU as described above. Two endometrial biopsies were obtained within that menstrual cycle on which no treatment was given. One biopsy was taken during the early secretory (LHC2) and another during the mid-secretory (LHC7) phase.
LH and P 4 serum levels were determined as described before (Croxatto et al. 2004) . For both parts of the study, each endometrial sample was divided into two and one piece was flash frozen in liquid nitrogen and stored at K80 8C for subsequent RNA isolation. The remainder piece was processed for histological assessment by an independent pathologist, under blind conditions, using the criteria described by Noyes et al. (1975) .
Isolation of RNA
Total RNA was isolated from each tissue sample using Trizol reagent (Invitrogen) according to the instructions from the manufacturer. RNA concentration was determined by absorbance at 260 nm (A 260 ) and purity by calculating the A 260 /A 280 ratio which varied between 1.8 and 2.1. The quality of the RNA was checked using the Agilent's Lab-on-a-Chip total RNA nano biosizing assay (Agilent Technologies, Inc., Palo Alto, CA, USA). The RNA integrity number was O9.0 for all samples analyzed.
GeneChip hybridization
Human Genome U133 plus 2.0 GeneChip oligonucleotide microarrays (Affymetrix, Sunnyvale, CA, USA) corresponding to 47 000 transcripts and variants, including 38 500 wellcharacterized human genes were used for gene expression analysis. Complementary RNA (cRNA) synthesis and array hybridization were performed according to the Affymetrix Expression Analysis Technical Manual. Briefly, 2 mg of purified Table 1 Characteristics of women participating in the study and parameters evaluated during the hormonal replacement cycle. All participating women had a BMI %30 and hemoglobin levels R12 g/dl. Mean and range for each parameter is indicated in parenthesis.
Group MIF/placebo (nZ7)
Group untreated LHC2/LHC7 (nZ7) 
Microarray data analysis
Intensity values for the probes generated with the Affymetrix GeneChip Miroarray suite v 1.4 were exported to the Partek Genomics suite v 6.3 beta software (Partek Incorporated, St Louis, MO, USA) to determine gene expression differences and statistical analyses. The sample size for this study was 14 subjects divided in two groups of seven. Since each women provided two endometrial samples (placebo/mifepristone or LHC2/LHC7), a total of 28 samples were analyzed in duplicate. Data from all 56 arrays were normalized using Robust Multichip Average method (Irizarry et al. 2003) and used for further statistical analysis. To identify the differentially expressed genes between mifepristone and placebo groups; and LHC2 and LHC7 samples, a pairwise t-test was applied. To assess the results, the P value !0.001 was used as a cutoff and a false discovery rate (FDR) of 1% was applied to the lists of genes. Finally, in addition to the appropriate correction for multiple testing, it was combined with a fold change of gene expression R2.0, calculated as the average log-ratio between two groups to determine up-and down-regulated genes between groups.
Overlapping genes from differentially expressed transcripts among comparisons were determined and graphically represented using Venn Diagrams.
Principal component analysis
Principal component analysis (PCA) is a statistical technique for simplifying large amounts of data derived from microarray analysis (Joliffe & Morgan 1992) . The method reduces the dimensionality of multivariate data while preserving as much of the relevant information as possible. As a form of unsupervised learning, relies entirely on the input data itself without reference to the corresponding target data. Mathematically is the transformation of the data to a new coordinate system with three dimensions, such that the variables from the new set (the principal components) are linear functions of the original variables. This simplification determines the key variables that explain the differences between samples based on the expression profiles, allowing the summarization and further analysis of the microarray data. We applied the unbiased PCA algorithm using the Partek software to all samples using 54 675 genes and ESTs represented on the microarray chip to look for expression patterns and underlying cluster structures.
Hierarchical clustering
Hierarchical clustering of endometrial samples was performed as another method of data structure visualization, using differentially expressed transcripts based on uncentered correlations with average linkage clustering. The resulting dendogram allows data structure visualization of endometrial samples according to total gene expression, revealing similar patterns of gene expression and relationships between the specimens and groups.
Over represented transcription factor binding sites detection in promoter regions of endometrial genes regulated by mifepristone For a systematic search for potential over represented transcription factor binding sites (TFBS), the promoter region of our genes of interest defined as the region proximal to the transcription-start site of genes transcribed by RNA polymerase II, was analyzed. For that we used three bioinformatic approaches and platforms to increase the likelihood of our results: MotifScanner on software TOUCAN (Aerts et al. 2003) , The Transcription Element Listening System (Cole et al. 2005) and Gene Annotation Tool to Help Explain Relationships (GATHER) (Chang & Nevins 2006) .
Functional clustering
The list of significantly regulated endometrial transcripts with mifepristone compared with placebo, obtained as described in the microarrays data analysis section, was used for functional clustering analyses in order to gain more insights about the biological process related to the regulated transcripts. The web-based tools Database for Annotation, Visualization and Integrated Discovery (DAVID) (Dennis et al. 2003) and GATHER (Chang & Nevins 2006) were used as described before (Tapia et al. 2011) . Both web-tool services obtain the biological meaning of submitted genes by retrieving their functional annotations from the Kyoto Encyclopedia of Genes and Genomes (Kanehisa et al. 2006) , Biocarta pathways (http:// www.biocarta.com) and Gene Ontology (GO) (Ashburner et al. 2000) databases. No directionality is associated with the obtained relationships (i.e. the function should not be interpreted as being increased or decreased).
Validation of microarray data by real-time RT-PCR
Verification of microarrays data was performed by real-time RT-PCR analysis of selected genes using an ABI PRISM 7000 sequence detection system according to the manufacturer's instructions (Applied Biosystems). Briefly, first-strand cDNA was synthesized from total RNA of each endometrial sample in duplicate by reverse transcription using the SuperScript III reverse transcriptase (Invitrogen), according to the manufacturer's protocol. Pre-validated primers and TaqMan probes (Assays-on-demand, PE Applied Biosystems) were used for all transcripts in Table 2 to determine their respective transcript levels and GAPDH was used as a reference housekeeping gene. Quantitative analysis was based on the relative quantification of each gene of interest in the endometrial samples from of each group by using the DDCT method (Livak & Schmittgen 2001) . Statistical significance was determined with the Wilcoxon two-sample paired signed rank test.
Results
Anthropometric and functional parameters of subjects in placebo and mifepristone treated cycles A total of 28 endometrial biopsies were obtained. Sixteen samples were obtained from mifepristone-and placebo-treated cycles (nZ7 for each group) with two 'wash-out' cycles in between. Another 14 samples were obtained from spontaneous cycles on LHC2 and LHC7 days (nZ7 for each of the 2 collection days).
All P 4 serum levels obtained on LHC7 were within expected values for a spontaneous normal menstrual cycle (O30 nmol/l) with no statistically significant differences between the mifepristone-and placebotreated groups (Table 1) in agreement with previous reports (Swahn et al. 1990) . No unscheduled bleeding or spotting was reported.
PCA and hierarchical clustering
PCA showed a clear segregation of samples according to their respective groups (Fig. 1A) . As expected, endometrial gene expression profiles from the LHC7 group clustered together with those from placebo group. Interestingly, biopsies taken on LHC2 grouped along with the mifepristone-treated samples. Unsupervised hierarchical clustering analysis was applied for gene expression profiles from endometrial samples obtained from microarrays data. A dendogram was generated with the data from the endometrial samples from all groups in a tree-structured graph. The dendogram obtained displayed a striking segregation of samples into two major clustering branches, one corresponding to the LHC2 and mifepristone groups and the other to the LHC7 and placebo groups (Fig. 1B) .
In the PCA and hierarchical clustering we found that the endometrial transcript profile during the window of implantation upon mifepristone administration is more similar to those obtained for early secretory endometrium during natural cycle. On the other hand, the endometrial transcript profiles from endometrial samples obtained in mid secretory phase upon placebo where indistinguishable from those obtained during the window of implantation during a non-treated spontaneous cycles and clustered separately from the other two groups.
Transcripts with differential expression in the endometrium after post ovulatory administration of mifepristone
We identified a total of 2119 transcripts corresponding to known genes whose expression altered significantly in the uterus at the time of implantation in response to mifepristone which represents a w4.7% of the total number of transcripts represented in the microarrays chip. In total, 766 and 1353 transcripts were up-and down-regulated respectively in receptive endometrium upon administration of mifepristone 200 mg on day LHC2 of the menstrual cycle compared with the time matched placebo group. In Tables 3 and 4 are shown the top 100 endometrial genes whose transcript levels increased and decreased respectively, upon mifepristone administration.
When the endometrial samples obtained on day LHC2 were compared with those obtained on day LHC7 during the same spontaneous cycle, 1915 transcripts were differentially expressed (w3.5% of transcripts assayed in the microarrays assay) with 893 and 1022 transcripts up-and down-regulated respectively. Seven hundred and seventy seven transcripts out of the total of differentially expressed genes from pre-receptive (LHC2) to receptive endometrium (LHC7) were common to those obtained with the administration of mifepristone compared with placebo ( Fig. 2) . Interestingly, 752 of them displayed opposite regulation directionalities whereas 25 changed in the same direction as mifepristone. It should be pointed out that such concordance of differentially expressed transcripts with opposed regulation is likely to be the main driver for the cluster structures found with PCA and hierarchical clustering.
Integration and cross-validation of human endometrial transcriptome during the window of implantation reported by different groups could increase the confidence in the detection of regulated transcripts for many more genes than is tractable with classical validation (Kemmeren et al. 2002 , Rhodes et al. 2002 . The available data sets comparing endometrial gene expression profiles during spontaneous cycles from the proliferative vs mid secretory phase (Kao et al. 2002 , Borthwick et al. 2003 , from early secretory vs mid secretory phase (Carson et al. 2002 , Riesewijk et al. 2003 , Mirkin et al. 2005 , Talbi et al. 2006 and with a single dose of mifepristone 200 mg on LHC8 after 6 and 24 h of administration vs placebo (Catalano et al. 2007) were contrasted with our data sets from microarrays analysis. We found 14 transcripts regulated by mifepristone (13 down-and 1 up-regulated) that also have been reported in the opposite direction during the window of implantation in at least four different studies and in our reference group (Table 5 ). The transcript CLDN4 was coincident with five reports but not significantly regulated in our reference group. Interestingly, we found only two coincident transcripts (MMP7 and CXCL12) in the study of Catalano et al. (2007) displaying the same regulatory direction with our study group and that have also been reported for the acquisition of receptivity; however the described regulatory behavior during spontaneous cycles is not the opposite in all of them.
Identification of overrepresented consensus sequences for TFBS sites of transcripts regulated by mifepristone
To identify potential common regulatory pathways in endometrial genes regulated by mifepristone, we performed an analysis for detection of over-represented promoter sequences using three bioinformatics tools. First, the potential TFBS were detected and then those statistically over-represented in our set of regulated endometrial genes were determined. The results are listed in Table 6 for up-and down-regulated transcripts respectively. Interestingly, DNA binding sites for seven transcription factors were identified as overrepresented in both increased and decreased transcripts whereas other 16 and 24 overrepresented TFBS where unique for up-and down-regulated genes respectively.
Functional clustering of endometrial transcripts regulated by mifepristone
In order to gain further understanding of the potential functional roles of dysregulated endometrial transcripts from group A, we obtained the functional annotations from each gene and determined the enriched processes associated with them from two different web-based tools. Within the up-regulated transcripts, the functional classifications related to cell adhesion and proliferation, were found to be statistically over-represented in both web-based tools used (Tables 7 and 8 ). The downregulated transcript list was not enriched with transcripts related to coincident functions in the two analysis performed for functional annotation clusters.
Real-time RT-PCR confirmation
In order to confirm differences in transcript levels found with the microarrays, five genes (CRISP3, GAL, MAOA, SLC39A14 and DKK1) whose mRNA steady-state level increased in the comparison LHC2 vs LHC7 and showed an opposite regulation upon mifepristone The profiles from the mifepristone group (red dots) cluster together with those for the LHC2 reference group whereas the samples from the placebo group cluster along with the LHC7 reference group. Hierarchical clustering analysis represented in a tree-like dendogram revealing the similarities on gene expression profiles of 28 endometrial samples. Each row represents a transcript and each column the gene expression profile of a particular endometrial sample. A clear segregation of samples into two major clustering branches, one with samples from mifepristone and LHC2 groups and the other with samples from placebo and LHC7 groups, is shown. Most gene expression profiles self-cluster together with others from their respective group. administration, were submitted to real-time RT-qPCR analysis. Additionally, transcript level for other three genes (SGB1D2, EVA1 and CRIP1) that were shown to decrease in the mifepristone-treated group but did not show significant variation in the comparison LHC2 vs LHC7, was analyzed by RT-qPCR. The mRNA levels for the eight genes analyzed were reduced in the mifepristone treated group compared with the placebo group in agreement with the microarray data (Fig. 3) . The transcript level of CRISP3, GAL, MAOA, SLC39A14 and DKK1 increased in the LHC7 group compared with the LHC2 group, however the level for SCGB1D2, EVA1 y CRIP1 was not statistically significant amongst these groups (Fig. 3) ; in line with the microarrays results.
Discussion
We determined the endometrial gene expression profile in human endometrium under four different conditions analyzing 54 675 transcripts that cover most of the known human genes reported. The endometrial samples were characterized at the molecular level organized in the unsupervised analyses PCA and hierarchical clustering. Each sample seems to have an expression profile that self-cluster with its own group. The gene expression profile of endometrial samples on LHC7 with mifepristone is similar to the one obtained with samples obtained in LHC2, and the profile of samples obtained in LHC7 with no treatment or with placebo are similar amongst them but different to the other two groups. For microarrays data validation, we confirmed by qPCR the transcript level of eight genes that were differentially expressed in the microarrays analysis during the window of implantation after mifepristone administration on LHC2. Although a relatively small number of transcripts were confirmed, considering that in other studies using the same microarrays platform we used have given a good correlation for gene expression confirmation, we consider such validation confers a reasonable validity to the groups of regulated transcripts.
The 2119 transcripts whose abundance was found altered 5 days after mifepristone administration on LHC2 in comparison with the placebo group is the most novel finding of this work. Since the most remarkable pharmacological property of mifepristone is to block P 4 action, we presume these genes are regulated either directly or indirectly by P 4 . Such presumption is in line with the finding that almost all transcripts that changed its level in the transition from LHC2 to LHC7 changed in the opposite direction of the mifepristone group compared with placebo. However such fact did not occur for 25 transcripts whose expression level changed significantly but in the same direction. This transcript regulation could be explained by an agonistic effect on these P 4 regulated transcripts. The agonistic effect of mifepristone has been described before in the endometrium from postmenopausal women with the induction of secretory changes after inducing proliferation with exogenous estradiol (Gravanis et al. 1985) . Such progestogenic effect of mifepristone has been documented in vitro in endometrial cell lines as well. In HeLa cells co-transfected with reporter genes and an expression vector with the PGR, an agonistic effect of mifepristone was described on gene expression (Meyer et al. 1990 , Tung et al. 1993 , Jackson et al. 1997 ) which depends on the isoform of the PGR mifepristone binds to and the cell context (Meyer et al. 1990 ). The gene expression profile analysis of Ishikawa cells in presence of P 4 or mifepristone showed that mifepristone induces a transcriptional behavior with both agonistic and antagonistic activity of P 4 (Tamm-Rosenstein et al. 2013). Regardless of the unexpected behavior of these 25 transcripts, it is unlikely they are involved in the anti-implantation effect driven by mifepristone.
The endometrium is composed of an heterogeneous population of cells including mesodermal-derived glandular and luminal epithelial cells that are supported by a basement membrane and uterine fibroblasts, vascular smooth cells, endothelial cells and lymphoid cells in the connective stroma. These cells have been described to respond differentially to the ovarian steroidal hormones. The endometrial samples analyzed in the present study, are processed combining all the cell types composing the tissue, hence it is difficult to put the regulated transcripts in context of a complex tissue. In this sense it is required further identification of the endometrial cell types expressing the genes of interest by techniques such as immunohistochemistry or in situ hybridization. An alternative approach has been to analyze separately the endometrial compartments during the window of implantation by laser capture microdissection (Torres et al. 2002 , Evans et al. 2012 , Evans et al. 2014 . These studies may contribute to the understanding on the regulation exerted by progesterone on specific endometrial compartments.
In the present study, we used two independent clustering strategies to analyze the microarrays data Table 5 Genes previously described to be regulated during the window of implantation in spontaneous cycles and/or regulated in endometrium of women with mifepristone administration on LHC8 that are coincident with our datasets. from the endometrial tissues and to analyze how samples cluster together based on similarities in their transcript profiles. Both clustering methods using different algorithms generated equivalent patterns of segregation of samples suggesting that the endometrial samples from day LHC7 obtained from women with mifepristone have a gene expression profile that does not progress from LHC2, highlighting the P 4 signaling restrain. When mifepristone is administered immediately after ovulation, it prevents the PGR and estrogen receptor down-regulation induced by P 4 which occurs during the luteal phase (Maentausta et al. 1993 ) suggesting a sustained endometrial stimulation by estrogen upon mifepristone administration. P 4 signaling inhibits the estrogen signaling pathways in the uterus (Hsueh et al. 1975 ) and this inhibitory relationship involving both hormone pathways orchestrate the regulatory mechanisms required for endometrial receptivity and embryo implantation. Amongst the regulated transcripts in the mid-secretory endometrium from women with mifepristone administration we found several genes involved in the P 4 signaling axis including modulators and effectors with down regulation of NCOA2 (SRC-2, (Mukherjee et al. 2006 , Jeong et al. 2007 ), IHH (Matsumoto et al. 2002 , Takamoto et al. 2002 , ERRFI1 (MIG6, (Kim et al. 2010) ) PTCH1 (Lee et al. 2006) and DKK1 ; and up-regulation of ESR1 (Curtis et al. 1999) , PRA (Conneely & Lydon 2000) , FKBP5 (Tranguch et al. 2005) , FOXO1A (Kim et al. 2005) , KLF9 (Simmen et al. 2004) and PTGS1 (Wang et al. 2004) .
With regard to the identification of key genes responsible for endometrial receptivity, Catalano et al. (2003) analyzed the endometrial gene expression profile under mifepristone stimulation using the endometrial tissue explant during the receptive phase. Explants were analyzed with a DNA microarray that investigated w1000 genes involved in cell adhesion, signaling, apoptosis, cell cycle regulation, extracellular matrix remodeling and angiogenesis. When mifepristone is administered during the midluteal phase of the menstrual cycle, it induces uterine bleeding due to endometrial breakdown within 72 h of administration in a similar way as P 4 withdrawal induces menstruation (Swahn et al. 1988 ). Catalano identified genes regulated by P 4 in human endometrium in vivo with the administration of 200 mg of mifepristone during mid-secretory phase. Under these circumstances, P 4 had already started to exert its effects in the endometrium and mifepristone induces menses within 48 h. Hence, the block of P 4 action during mid-secretory phase not only renders the endometrium unreceptive but also induces processes involved in menstruation generating a confounding effect that difficult the identification of transcripts involved in endometrial receptivity. When mifepristone is administered immediately after ovulation, the length of the menstrual cycle and plasmatic levels of estradiol and P 4 are not affected (Swahn et al. 1990 ), however induces a dramatic effect on endometrial development (Dockery et al. 1997 , Danielsson et al. 2003 . For these reasons we chose for the present study, administering mifepristone on the Enriched functional annotations found in GATHER (Table 7) and Database for Annotation, Visualization and Integrated Discovery (Table 8 ) appear in bold. early secretory period (i.e. LHC2). Under these circumstances, P 4 action was antagonized from the beginning of the luteal phase and thus, avoiding the induction of early menses reflecting a lack of P 4 action in mid-secretory endometrium. After 5 days of mifepristone administration is difficult to speculate about the proportion of PGRs that remain blocked in the endometrium since to our knowledge there is no report regarding this matter so far. The studies performed with mifepristone administration during the early luteal phase showed an out-of-phase endometrial development in spite of high circulating P 4 , suggesting a persistent block of the PGR (Swahn et al. 1990 ). The administration of mifepristone (200 mg) in LHC2 reaches a peak circulating level of w0.3-0.4 mmol/l within 2 h (Sarkar 2002) and is able to alter uterine gene expression in early pregnancy as early as 6 h after oral administration (Critchley et al. 1996) . However, considering that plasmatic half-life of mifepristone is 30 h (Sarkar 2002) and its concentration (as well as its metabolites that retain anti-progestin properties) is maintained at the micromolar level for at least 72 h (Heikinheimo et al. 2003) with detectable levels in circulation for 6-7 days (Sitruk-Ware & Spitz 2003) we believe that most of the P 4 effects are still abrogated in the endometrium on LHC7. Thus, the endometrial phenotype observed 5 days after mifepristone administration results from the disruption of the events directly and indirectly driven by P 4 from the early secretory phase until the window of implantation. Mifepristone also has affinity and antagonistic effects on the glucocorticoid receptor (Bertagna et al. 1984) present in human endometrial stroma (Bamberger et al. 2001 , Sitruk-Ware & Spitz 2003 . However for mifepristone to exert an anti-glucocorticoid effect, the dose that has to be administered is in the range of 5-20 mg/kg (Gaillard et al. 1984 , Cadepond et al. 1997 , Sitruk-Ware & Spitz 2003 , Johanssen & Allolio 2007 which is a much higher dose than the used dose in the present study. Hence, we presume that the described changes on gene expression are mostly attributable to a blockade of P 4 action without ruling out that some of them are driven by mifepristone regulation of the glucocorticoid receptor.
Our microarrays analysis identified 1915 transcripts differentially expressed in the transition from the prereceptive to receptive endometrium (i.e. from LHC2 to LHC7) in a spontaneous cycle. This number represents a 3.5% of the total number of analyzed transcripts. Other reports have using DNA microarrays technology have described a number of endometrial transcripts regulated during the receptive phase (highest P 4 levels) compared with earlier stages of the secretory phase (low P 4 levels) (Carson et al. 2002 , Riesewijk et al. 2003 , Mirkin et al. 2005 , Talbi et al. 2006 or proliferative phase dominated by estrogen (Kao et al. 2002 , Borthwick et al. 2003 , suggesting a hormonal control of these genes. We contrasted our results with the reports afore mentioned. We found that the transcript for SPP1 was downregulated upon mifepristone while it appears up-regulated in the six other studies we compared our results in our reference group (LHC2/LHC7). Other six transcripts are regulated with mifepristone and are also regulated in the opposite direction in other five reports as well as in our reference group. Given the rather small number of coincident endometrial transcripts across the different studies reported during the window of implantation (Tapia et al. 2011) ; such concordance of transcript regulation with mifepristone validates our results.
When P 4 action was blocked with mifepristone administration during the early luteal phase, the number of regulated transcripts during the receptive phase (2119, w3.9%) was similar to the one that change during the window of implantation. When we compared the identity of such transcripts, we found that only a sub group of 777 were regulated in both comparisons. A rather small fraction of the differentially expressed genes upon mifepristone administration were shown to be associated with the acquisition of endometrial receptivity during a spontaneous cycle. To rule out the possibility that this proportion of overlapping transcripts was underestimated as a result of a significant amount of false-positive in each comparison, we performed the statistical analyses with a higher threshold (FDR 1%, FC R4) and found 594 and 470 regulated transcripts in the mifepristone and reference group (LHC2/LHC7) respectively. Only 130 transcripts (22%) were common in both the groups and all of them displayed opposite regulatory direction between groups, except for three down-regulated transcripts in the mifepristone group, supporting our main finding. Endometrial receptivity results from the expression and repression of genes controlled by ovarian steroidal hormones and other factors; however it is well established that P 4 is a critical determinant of endometrial function during the window of implantation (Rosario et al. 2003) . Under this premise, it is surprising that only about a third of the genes that change its expression level at the moment of endometrial receptivity are also regulated under the action of mifepristone. A possible explanation to this is that not all the genes regulated during the window of implantation are necessarily involved in the acquisition of receptivity and it is possible that the gene regulation observed in a subgroup of transcripts is in response to other chemical messengers present during the secretory phase, independently of P 4 . The endometrium is exposed to important levels of estradiol and relaxin of ovarian origin that could influence and control endometrial gene expression. The function of estradiol during the secretory phase in humans is not clear and its role on acquisition of receptivity is controversial. Using the oocyte donation model in women without ovarian function, Younis et al. (1994) showed that estrogen privation during the secretory phase does not affect the development of endometrial morphology. On the other hand, other study using estrogen receptor antagonism with clomiphene starting 2 days after the LH peak in spontaneous cycles and maintained until an endometrial biopsy was taken on day 13 showed a consistently delayed histological dating (Fritz et al. 1987) . In addition, endometrial tissue explants incubated with P 4 or in combination with estradiol showed that the expression of a group of genes whose expression can be modulated only with P 4 , is sensitive to its exposure to estradiol suggesting that endometrial expression of some genes regulated by P 4 are sensitive to the presence of estradiol (Dassen et al. 2007b) . Circulating relaxin (RLX) levels rise during the luteal phase (Bond et al. 2004 , Hayes 2004 and its detection in the endometrium during natural cycles coincide with the period of endometrial receptivity (Yki-Jarvinen et al. 1985) suggesting a role in the early events of embryo implantation. Several studies show that RLX exerts a wide range of effects on the human endometrium mediating differentiation, vascularization and immunomodulation in this tissue (Goldsmith & Weiss 2009 Bell et al. 1991) , glycodelin (Tseng et al. 1999) and vascular endothelial growth factor (VEGF; Unemori et al. 1999 , Palejwala et al. 2002 . The results obtained in the present study cannot distinguish between genes that are regulated by P 4 and those whose transcript levels are regulated by the presence of estrogens, relaxin or other factors.
With regard to the functional clustering of regulated transcripts under mifepristone, the terms 'cell adhesion' and 'proliferation' were most consistent within the up-regulated transcripts. It has to be noted that the association of a particular function with a set of up-or down-regulated genes should not be interpreted as the function being regulated in the direction of the transcript level change. P 4 has been shown to completely inhibit estrogen-induced epithelial cell proliferation and DNA synthesis which is in line with the functional clustering related with 'proliferation.' Moreover, a functional analysis of mifepristone responsive genes in Ishikawa cells identified a signaling pathway associated with adhesion and cellto-cell interactions (Tamm-Rosenstein et al. 2013) , which is in line with the term 'cell adhesion' we found. In relation to the over-represented TBFS analysis in the promoter regions of endometrial genes regulated by mifepristone, it is interesting that the cognate sequence for PGR was not over represented, suggesting that the transcriptional regulation exerted by the PGR is presumably mostly indirect.
In conclusion, in this study we determined changes in endometrial gene expression during the receptive period associated with a pharmacologic blockade of P 4 since LHC2. Approximately a 37% of the genes regulated with mifepristone appear to be also associated with endometrial receptivity considering those whose transcript level also changed during the window of implantation (i.e. from LHC2 to LHC7). Interestingly, out of the total of coincident transcripts with differential expression, almost all of them (96.8%) were found to be oppositely regulated, suggesting they are target of progesterone regulation and underlining their potential role in endowing the endometrium its receptive capacity. Additionally, more than 1000 transcripts whose endometrial levels change during period of receptivity see not to be regulated directly or indirectly by P 4 considering that mifepristone did not interfere with this change. Further analysis should establish the cellular phenotypes and temporal dynamics involved in transcripts regulation as well as the function in the uterus of each gene identified in this study to elucidate the mechanisms regulating endometrial receptivity.
